CAJ | 학술논문

目的：探讨艾愈胶囊辅助治疗乳腺癌的有效性、安全性及经济性。方法：选取2012年2月至2014年1月行乳腺癌化疗的患者150例，分为观察组90例、对照组60例。化疗方案参考乳腺癌美国国立综合癌症网络（NCCN）指南方案。在此基础上，对照组给予安慰剂胶囊，3粒/次，每天3次，口服；治疗组给予艾愈胶囊，每次3粒，每日3次，连续42 d为1个周期。比较两组的疗效、临床症状改善情况、毒副反应并进行成本-效果分析。结果：治疗后，治疗组总有效率（66.7％）明显高于对照组（46.7％）；治疗组临床症状改善率（87.7％）明显高于对照组（66.7％）；治疗组患者白细胞下降、恶心呕吐的发生率明显低于对照组；治疗组的成本-效果比明显低于对照组，差异均有统计学意义（P＜0.05）。结论：艾愈胶囊辅助化疗治疗乳腺癌疗效确切、不良反应少，是一种有效且经济的治疗方案，值得临床推广应用。
목적：탐토애유효낭보조치료유선암적유효성、안전성급경제성。방법：선취2012년2월지2014년1월행유선암화료적환자150례，분위관찰조90례、대조조60례。화료방안삼고유선암미국국립종합암증망락（NCCN）지남방안。재차기출상，대조조급여안위제효낭，3립/차，매천3차，구복；치료조급여애유효낭，매차3립，매일3차，련속42 d위1개주기。비교량조적료효、림상증상개선정황、독부반응병진행성본-효과분석。결과：치료후，치료조총유효솔（66.7％）명현고우대조조（46.7％）；치료조림상증상개선솔（87.7％）명현고우대조조（66.7％）；치료조환자백세포하강、악심구토적발생솔명현저우대조조；치료조적성본-효과비명현저우대조조，차이균유통계학의의（P＜0.05）。결론：애유효낭보조화료치료유선암료효학절、불량반응소，시일충유효차경제적치료방안，치득림상추엄응용。
OBJECTIVE:To evaluate the efficacy,safety and economics of Aiyu capsules as an adjuvant therapy for breast can-cer. METHODS:A total of 150 patients undergoing chemotherapy for breast cancer from Feb. 2012 to Jan. 2014 were enrolled, with 90 cases assigned to observation group and another 60 to control group. The chemotherapy for breast cancer was performed in accordance with U.S. National Comprehensive Cancer Network(NCCN)guidelines. Additionally,the control group received place-bo capsules (3 capsules/time,3 times a day) orally and the treatment group received Aiyu capsules (3 capsules/time,3 times a day)orally for 42 days(one cycle). The efficacy and improvement of clinical symptoms in the two groups were compared and the toxicity and cost-effectiveness analysis were analyzed. RESULTS:The total effective rate of the treatment group(66.7%)was sig-nificantly higher than in the control group (46.7%);the total rate of clinical symptoms improvement in the treatment group (87.7%)was significantly higher than in the control group(66.7%);the incidences of toxicity including reduction of white blood count,nausea and vomiting were significantly lower in the treatment group than in the control group;the cost-effectiveness ratio in the treatment group was significantly lower than in the control group. All the differences were statistically significant (P<0.05). CONCLUSIONS:Aiyu capsules as an adjuvant therapy for breast cancer is proved to be safe,effective and economical which thus is worthy of clinical recommendation.